Aptus Pharma Ltd. Announces Increase in Authorized Share Capital and Bonus Equity Share Issue
Aptus Pharma Ltd. announced on March 26, 2026, that its Board of Directors approved an increase in the company’s Authorized Share Capital and a bonus equity share issue in a ratio of 3:2.The bonus equity share issue will involve the capitalization of ₹10,29,00,000 from the company's Securities Premium Account, resulting in the issuance of 1,02,90,000 equity shares with a face value of ₹10 each. This translates to a total issuance value of ₹10,29,00,000.
Share Capital details are presented in the table below:
| Particulars | Pre Bonus Issue | Post Bonus Issue | |
|---|---|---|---|
| Share Capital | |||
| No. of Shares | 68,60,000 | 1,02,90,000 | |
| Face Value (in Rs.) | 10 | 10 | |
| Total Amount of Shares (in Rs.) | 6,86,00,000 | 17,15,00,000 |
The Board also approved a draft Postal Ballot Notice to seek member approval for the increase in Authorized Share Capital and the bonus equity share issue. A record date for determining entitlement to the bonus shares will be announced later. The bonus shares are expected to be credited/dispatched within two months from the date of approval, approximately by May 23, 2026.
Central Depository Systems Limited (CDSL) has been appointed as the agency for providing remote e-voting facility for the Postal Ballot process. The Board meeting commenced at 5:00 P.M. and concluded at 7:15 P.M.
Further details as per SEBI requirements are available in Annexure - I. AB KB & Co. Chartered Accountants certified that the company has adequate reserves to facilitate the bonus share issue.
Source:
Disclaimer: Due care and diligence have been taken in compiling and presenting news and market-related content. However, errors or omissions may arise despite such efforts.
The information provided is for general informational purposes only and does not constitute investment advice, a recommendation, or an offer to buy or sell any securities. Readers are advised to rely on their own assessment and judgment and consult appropriate financial advisers, if required, before taking any investment-related decisions.